Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356181 | PMC |
| http://dx.doi.org/10.1016/j.prdoa.2022.100157 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Network-wide effects of pallidal deep brain stimulation normalised abnormal cerebellar cortical activity in the dystonic animal model.
Neurobiol Dis
December 2024
Oscar Langendorff Institute of Physiology, University Medical Centre Rostock, Rostock, Germany. Electronic address:
Background: Deep brain stimulation (DBS) targeting globus pallidus internus (GPi) is a recognised therapy for drug-refractory dystonia. However, the mechanisms underlying this effect are not fully understood. This study explores how pallidal DBS alters spatiotemporal pattern formation of neuronal dynamics within the cerebellar cortex in a dystonic animal model, the dt hamster.
View Article and Find Full Text PDFBiallelic variants in the cause mitochondrial respiratory complex assembly defects associated with Leigh syndrome in probands.
Mol Genet Metab Rep
December 2024
Eye Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Background: Variants in have been reported to be associated with Leigh syndrome. However, further expansion of the -phenotype and variants spectrum of -related Leigh syndrome are still required.
Methods: Two patients diagnosed with Leigh syndrome were recruited, and whole-exome sequencing was performed to identify the genetic variants responsible for the abnormal gait, dystonia, and bilateral basal ganglia lesions, followed by validation using Sanger sequencing.
Optimal botulinum toxin therapy of dystonia in Germany: what would it cost?
J Neural Transm (Vienna)
December 2024
IAB - Interdiciplinary Working Group for Movement Disorders, Hamburg, Germany.
Botulinum toxin (BT) therapy is the therapy of choice for most forms of dystonia. We want to describe its costs, if all dystonia patients in Germany would have access to optimal BT therapy. For this, we combined the latest data on epidemiology of dystonia and dosing of BT therapy for dystonia.
View Article and Find Full Text PDFSpasmodic dysphonia: the need for a combined neurological and phoniatric approach.
J Neural Transm (Vienna)
December 2024
IAB - Interdisciplinary Working Group for Movement Disorders, Hamburg, Germany.
Spasmodic dysphonia (SD) is now generally considered to be a task-specific focal dystonia. For the first time, we wanted to explore the relationship between SD and dystonia from a combined neurological and phoniatric perspective. For this, we studied 115 patients with non-psychogenic SD by a combined neurological and phoniatric evaluation.
View Article and Find Full Text PDFData mining in FAERS: association of newer-generation H1-antihistamines with nervous system disorders.
BMC Pharmacol Toxicol
December 2024
Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Background: H1-antihistamines are widely used to treat symptoms depending on histamine release in a variety of conditions. However, neurological adverse events have been reported in post-marketing surveillance studies and there are limited literatures comparing the neurological disorders associated with newer-generation H1-antihistamines from real-world datasets.
Aims: We performed a comparative analysis of nervous system disorders and several newer-generation H1-antihistamines including: cetirizine, loratadine, levocetirizine, desloratadine and fexofenadine.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!